Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News WPD Pharmaceuticals Inc C.WBIO

Alternate Symbol(s):  WPDPF

Industrials Technology
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

Recent & Breaking News (CSE:WBIO)

WPD Pharmaceuticals (CSE:WBIO) shows 100 per cent survival may be possible with Annamycin drug

Brieanna McCutcheon  February 5, 2021

WPD Pharmaceuticals' Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug

GlobeNewswire February 5, 2021

WPD Pharmaceuticals to Participate in the 7?? Annual LSX World Congress, a Leading Global Healthcare and Life Sciences Forum

GlobeNewswire January 28, 2021

WPD Pharmaceuticals Contracts Clinigen Clinical Supplies Management to Perform QP Certification of Berubicin for the Clinical Trials Authorization

GlobeNewswire January 14, 2021

WPD Pharmaceuticals to Collaborate With IAG to Deploy Artificial Intelligence and Quantitative Imaging to Assess the Effects of Berubicin

GlobeNewswire January 6, 2021

Some of the Top Pharmaceutical Companies to Watch in New Year 2021

Livemoney January 6, 2021

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

GlobeNewswire October 26, 2020

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

GlobeNewswire October 15, 2020

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and Receives $106,626 Government Covid-19 Cash Assistance

GlobeNewswire October 5, 2020

US FDA Starting to Grant Fast-Track Designation for Glioblastoma Treatments

Livemoney September 16, 2020

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

GlobeNewswire September 16, 2020

Five Pharmaceutical Stocks Investors May Want to Keep an Eye On

Livemoney September 9, 2020

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

GlobeNewswire September 9, 2020

Five Cancer Treatment Companies to Watch in 2020

Livemoney September 1, 2020

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous Tumors using WPD101 Drug Candidate

GlobeNewswire September 1, 2020

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

GlobeNewswire August 17, 2020

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

GlobeNewswire July 28, 2020

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

GlobeNewswire July 23, 2020

WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066

GlobeNewswire July 6, 2020

WPD Pharmaceuticals Licensor Announces Confirmatory in Vitro Analysis of WP1122

GlobeNewswire June 22, 2020